PLLA aftercare is the part of the treatment you do not control, which is why it is the part that deserves the most planning. Everything else — reconstitution, plane, volume, technique — happens with the syringe in your hand. The massage happens at the patient's kitchen table, five days after they left your clinic, and whether it happens at all depends entirely on how well you set it up.
The instruction most injectors know is the 5-5-5 rule: massage the treated area five minutes, five times a day, for five days. It is taught, it is on aftercare sheets everywhere, and it is genuinely part of what I teach — the only real downside of this treatment is that the patient has to be very compliant, and the massage is where that compliance shows.
This page does two things: it states exactly what the current FDA-approved labelling says, verified against the label itself, and it sets that instruction inside the full set of levers that determine whether a patient develops a nodule. The massage is one of them. It is not the only one, and the others are the ones you control.
What the current labelling actually says
Checked against the approved US labelling for injectable poly-L-lactic acid as of PMA supplement P030050/S039, the panel-track approval of 25 April 2023 that added the cheek indication — the most recent published labelling for the device.
The 5-5-5 patient massage instruction is still in the label. Verbatim, in the post-treatment care section:
"It is recommended that the patient should massage the treated areas for five minutes, five times per day for five days after the injection session to promote a natural-looking correction."
And again in the patient instructions section:
"It is recommended to massage in a circular fashion the treated areas for 5 minutes, 5 times per day for 5 days following any injection session, according to the healthcare professional's advice."
It is not the only massage instruction in the label, and the other two are the ones more often skipped:
- During the session: the treatment area should be massaged in a circular fashion after every three to four injections, to distribute the product evenly.
- At the end of the session: the clinician should manually massage the treatment area in a circular fashion for a minimum of two minutes, using a facial moisturiser.
So 5-5-5 is current labelled guidance, and it sits alongside two clinician-performed massage steps that matter at least as much. Most aftercare sheets carry the first and omit the other two.
Where the first "5" went
There is a part of the original rule most people have forgotten was in it.
The "5-5-5" formulation traces to Goldman's 2011 technique paper, where it was 5 mL, 5 minutes, 5 days — the first five was the reconstitution volume (Goldman MP. Dermatol Surg. 2011;37:688–693. doi:10.1111/j.1524-4725.2011.01975.x). That first five is the element that has moved.
Current labelling permits two reconstitution protocols: 5 mL of sterile water for injection, left to stand at least two hours and usable for up to 72 hours; or 8 mL of sterile water with the optional addition of 1 mL of 2% lidocaine, for immediate use. The plane and needle follow the volume — 26 G into the deep dermis for the 5 mL preparation, 25 G into the subdermal region for the 8 mL.
Published practice has moved further still. A 2026 scoping review of PLLA nodule management in Cureus summarises the consensus position as 8 to 10 mL per vial for facial applications and 16 to 18 mL or higher for the body, with reconstitution times starting from two hours and longer where practical (Flores Rodríguez JC, Porras Zamora BM, Rico Macías NM, et al. Cureus. 2026;18:e110742. doi:10.7759/cureus.110742).
The dilution volume is not a stylistic preference. It is the variable with the clearest relationship to nodule rate.
Why nodules form, and what is actually modifiable
Nodules after PLLA are not one entity. The label distinguishes two onset windows and they behave differently:
- Early nodules, arising within three to six weeks of treatment. The label attributes these to dilution and injection technique — specifically superficial injection and over-correction — and states they may be minimised by adhering to proper dilution and injection technique, and that massaging to ensure proper distribution may also help. Most resolve spontaneously.
- Delayed nodules, typically manifesting within three to four months, and sometimes far later — case reports in the scoping review describe onset at 12, 18 and 24 months. These skew toward inflammatory, immune-mediated and biofilm-associated mechanisms and often require intervention.
Delayed nodules and granulomatous reactions are not rare enough to ignore: one retrospective analysis of 7,659 patient outcomes put them at 8.3% of all filler-related adverse events (Kern JA, Kollipara R, Hoss E, et al. Dermatol Surg. 2022;48:551–555).
The modifiable factors look like this:
1. Dilution volume — the strongest lever. The scoping review's own conclusion is that appropriate dilution, correct reconstitution, proper injection depth and non-bolus delivery are the most important modifiable aspects, and that the volume of dilution plays a critical preventive role compared with massage alone. A chart review of alternative reconstitution volumes reported a nodule rate of 1.3% with 10 to 12 mL, against 8% with the standard protocol (Palm M, Mayoral F, Rajani A, et al. J Drugs Dermatol. 2021;20:638–). Earlier practice using only 2 to 3 mL of sterile water was associated with very high nodule rates.
2. Reconstitution time. Consensus recommends at least two hours, with longer where practical, to improve particle dispersion.
3. Plane and delivery. Deep subcutaneous placement with retrograde fanning and tunnelling, not bolus deposition. Superficial placement is a named cause of early nodules; the label directs that if the injected area blanches immediately or shortly after injection, the needle was too superficial — remove it, massage the area in a circular fashion, and if blanching does not disappear, do not re-inject that area.
4. Under-correction. The label is unambiguous: the contour deficiency should be under-corrected, never fully corrected or over-corrected during any injection session. Over-correction is listed alongside superficial injection as a cause of early nodules. This is also why treating before the labelled interval matters — you are stacking product on an effect that has not yet expressed.
5. Site selection. Increased caution in highly mobile or anatomically risky regions: periorbital, temporal, glabella, nasolabial folds and the prejowl sulcus. Periorbital PLLA appears repeatedly in the granuloma case literature.
6. Massage — yours and the patient's. Distribution is the mechanism massage serves, and it runs across all three labelled steps: the circular massage after every three to four injections during the session, the minimum two minutes with moisturiser at the end of the session, and then the patient's 5-5-5 at home. The two you perform are the ones most often skipped, and they happen while the product is at its most mobile.
Putting the aftercare plan together
Prevention is a package, and the massage is one part of it.
Instruct the 5-5-5 clearly. It is in the current approved labelling, and it is what I teach. "Massage the area five minutes, five times a day, for five days" is an unambiguous instruction, and patients follow unambiguous instructions better than hedged ones. Set it up at consultation so the patient arrives expecting it, not at discharge as one more line on a leaflet.
Do your own massage properly. The two clinician-performed steps — after every three to four injections during the session, and a minimum of two minutes with moisturiser at the end — are under your control and are frequently skipped. Most of the distribution happens while the patient is still in your chair.
Build the rest of the package before the patient leaves. Dilution volume, reconstitution time, plane, non-bolus delivery, under-correction and site selection are all settled before the aftercare sheet is handed over, and they are where the majority of your nodule risk is decided.
Do not read a nodule as non-compliance. A patient can follow the aftercare exactly and still develop a nodule, particularly a delayed one. If that happens, review your dilution and your plane rather than the patient's honesty.
This aftercare protocol reflects Maritza Mejia's clinical practice as taught in Empire Medical Training's hands-on curriculum, alongside the current approved labelling quoted above. Technique is learned under supervision; this article is educational and is not a substitute for training. Labelling is current as of publication; verify against the manufacturer's instructions for use before treating.
Managing a nodule when one appears
The 2026 scoping review proposes a severity-graded pathway, and it is a sensible structure to adopt.
Grade 1 — mild. A single, non-tender palpable nodule under 5 mm, no skin change, no functional impairment. Reassurance, massage, warm compresses, short-term clinical observation. Many resolve spontaneously or stay clinically stable.
Grade 2 — moderate. Multiple or persistent nodules, mild tenderness or erythema, roughly 5 to 10 mm, cosmetically significant. Intralesional triamcinolone acetonide, commonly 5 to 10 mg/mL, with repeat sessions at around four-week intervals according to response.
Grade 3 — inflammatory or immune-mediated. Combined approaches — intralesional corticosteroid, 5-fluorouracil, systemic corticosteroid, or immunomodulating agents such as hydroxychloroquine.
Two cautions that sit above the ladder. Culture before steroids where infection or biofilm is plausible — atypical mycobacterial infection after PLLA is documented and is made worse by immunosuppression. And imaging is now a reasonable step: high-frequency ultrasound helps localise filler deposits, assess lesion depth and distribution and distinguish product from inflammatory tissue, and the scoping review grades that evidence moderate to high, higher than most of the therapeutic evidence.
Note what is missing from the whole ladder: hyaluronidase. PLLA is not reversible. There is no dissolving conversation to fall back on, which is precisely why the prevention side of this page matters more than the management side.
What to give the patient in writing
Keep it short enough to be followed.
- Ice within the first 24 hours, wrapped, never in direct contact with skin.
- Massage in a circular fashion, five minutes, five times a day, for five days.
- Expect swelling and bruising. Expect the treated area to look full today and to return to its starting appearance within days.
- Make-up may be applied a few hours after treatment if there are no complications.
- Avoid sun and UV lamp exposure until initial swelling and redness have resolved.
- Report any lump, colour change or tenderness rather than waiting for the next appointment.
That last line is the one worth emphasising verbally. Small papules in the treated area may be non-visible and asymptomatic, noticed only on palpation, and are described in the labelling as a possible outcome of treatment — but visible nodules with redness or colour change are a reason to be seen, not a reason to wait.
Where this is trained
Reconstitution, dilution decisions, plane and the tactile business of retrograde fanning are hands-on skills, and the nodule literature is essentially a list of what happens when they are done approximately. Empire's Facial Contouring Injectables workshop covering Sculptra, Radiesse, exosomes and PDRN is where the PLLA protocol is taught under supervision, and Complete Facial Aesthetic Training sets it in the context of a full-face plan. For patients wanting an orientation before consultation, Empire's Sculptra overview is the appropriate page.
Related guides in this cluster
Part of Treatment Planning and Layering.
Clinical GuideThe Collagen Stimulator Landscape: Skin Boosters vs Biostimulators vs Fillers, ComparedSkin boosters vs biostimulators vs fillers, compared by goal, plane, onset and failure mode — a four-category clinical matrix for injec
Clinical GuideChoose by Tissue Diagnosis, Not by Trend: A Collagen Biostimulator Decision TreeA collagen biostimulator decision tree for injectors — four tissue findings, four products, and the five-point compass behind every sel
Clinical GuideThe Biostimulator Results Timeline: Why Three Months, and How to Set It at ConsultationThe biostimulator results timeline injectors should set at consultation: why day-zero fullness is water, when collagen shows, and the s
Train with Empire
This guide is clinical education. The technique behind it is taught hands-on, on live patients, with faculty beside you.
Explore Anatomical-Based Aesthetics Training →Disclaimer
This article reflects the clinical opinions and experience of Maritza Mejia, FNP, an independent faculty member contributing to Empire Medical Training's curriculum. The views expressed are the author's own and do not necessarily represent those of Empire Medical Training.
It is professional education, not medical advice, and is no substitute for hands-on training or independent clinical judgment. Licensed clinicians remain responsible for their own patient selection, technique and outcomes, for verifying current product labelling, and for practising within their scope and applicable law. Empire Medical Training accepts no liability for reliance on this content.